Sandoz Fights Amgen Enbrel Patent

Law360, New York (June 26, 2013, 5:24 PM EDT) -- Amgen Inc. and Hoffman-La Roche Inc. were struck with a California federal lawsuit Tuesday from Sandoz Inc. that says a generic form of arthritis drug Enbrel is not infringing two patents and a delay in the patents' issuance renders them invalid.

The disputed patents, for formulations of the pharmaceutical compound etanercept, are not valid because they were improperly issued more than 15 years after Hoffman-LaRoche first filed, the complaint says. By allowing so much time to elapse before approval, the U.S. Patent and Trademark Office damaged...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.